CASI Pharmaceuticals (NASDAQ: CASI) is one of 196 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare CASI Pharmaceuticals to similar businesses based on the strength of its analyst recommendations, earnings, valuation, institutional ownership, profitability, risk and dividends.

Analyst Recommendations

This is a summary of current ratings for CASI Pharmaceuticals and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CASI Pharmaceuticals 0 0 2 0 3.00
CASI Pharmaceuticals Competitors 790 2961 6462 145 2.58

CASI Pharmaceuticals presently has a consensus price target of $3.00, indicating a potential upside of 69.49%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 5.16%. Given CASI Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe CASI Pharmaceuticals is more favorable than its rivals.

Valuation & Earnings

This table compares CASI Pharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
CASI Pharmaceuticals N/A -$8.40 million -11.80
CASI Pharmaceuticals Competitors $207.80 million -$2.19 million -0.33

CASI Pharmaceuticals’ rivals have higher revenue and earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares CASI Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CASI Pharmaceuticals N/A -46.41% -32.99%
CASI Pharmaceuticals Competitors -3,686.25% -415.85% -47.39%

Risk & Volatility

CASI Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, CASI Pharmaceuticals’ rivals have a beta of 1.67, suggesting that their average stock price is 67% more volatile than the S&P 500.

Insider and Institutional Ownership

3.8% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 13.0% of CASI Pharmaceuticals shares are owned by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

Receive News & Stock Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.